Sanofi’s New CEO Brandicourt Will Face Diabetes And Launch Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
But analysts say Olivier Brandicourt’s breadth of experience and cardiology strengths bode well for Sanofi, which can now close an unpleasant and very public boardroom shakeup and get on with needed business.
You may also be interested in...
Sanofi Says Au Revoir To Viehbacher, But Is It Committing A Faux Pas?
The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.